ONC:NASDAQ
BeOne Medicines AG
$364.02
arrow_upward
+0.34%(+1.24) 1D
$364.02
0.00% (0.00)
bedtimePagkalipas ng oras ng trabaho
Sarado: Okt 7, 4:00:00 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa ONC...
Buksan
$360.01
Mataas
$367.57
Mababa
$359.41
Mkt. cap
44.66B
Avg. na dami
374.43K
Dami
137.23K
Mataas nang 52-wk
$385.22
Mababa nang 52-wk
$253.95
Beta
0.61
Mga natitirang share
109.79M
Bilang ng mga empleyado
12K
Buksan
$360.01
Mataas
$367.57
Mababa
$359.41
Mkt. cap
44.66B
Avg. na dami
374.43K
Dami
137.23K
Mataas nang 52-wk
$385.22
Mababa nang 52-wk
$253.95
Beta
0.61
Mga natitirang share
109.79M
Bilang ng mga empleyado
12K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
MarketBeat
·
9 oras ang nakalipas
BeOne Medicines (NASDAQ:ONC) Stock Rating Cut to Hold at Zacks Research
AD HOC NEWS
·
19 oras ang nakalipas
BeOne Medicines stock gained 1.00 percent on October 5 as targets rose
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Tungkol sa BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Mga Empleyado12K
ItinatagOkt 28, 2010
Headquarters-
Sektor-
Websitebeonemedicines.com